ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 447

High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis

Claire I. Daien1,2, Sarah Gailhac3, Thibault Mura4, Bernard Combe2, Michael Hahne1 and Jacques Morel5, 1IGMM, CNRS UMR5535, Montpellier, Montpellier, France, 2Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, 3Igmm UMR3555, CNRS, Montpellier, France, 4CIC, Hopital Gui De Chauliac, Montpellier, France, 5Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, B cell memory, biomarkers and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Tumor necrosis factor (TNF) inhibitors (TNFi) are effective treatments for rheumatoid arthritis (RA). Some reports suggested that TNFi affect B cell homeostasis.  We studied the effect of TNFi on peripheral B cells and elucidated B cell related biomarkers to predict TNFi response.

Methods: Peripheral B cells were analyzed for expression of CD19, CD27, CD38, IgD in 31 healthy donors and 96 RA patients, including 21 patients who were followed 3 months after TNFi introduction. We compared B cell subsets between patients with RA and controls; TNFi and non TNFi users as well as before and after TNFi introduction in RA patients. We also aimed to identify phenotypes associated with EULAR response.

Results: B cell subsets in blood were influenced by age and glucocorticoids doses. After adjustment on age, gender and glucocorticoid doses, patients with RA were found to have similar B cell subset frequencies as controls. No significant effect of TNFi on B cell repartition was found when comparing TNFi and non TNFi users at baseline or patients before and after TNFi introduction. TNFi responders at 3 months had significantly higher percentage of CD27+ memory B cells at baseline and those with CD27+ above 26% at inclusion were 4.9 (1.3-18.6) more likely to respond TNFi treatment. CD27+ cells produced 3 times more TNF alpha than naïve B cells which was correlated with IFN gamma-producing CD4+in patients free of TNFi.

Conclusion: High levels of memory B cells at baseline were associated with response to TNFi which may be related to the  activation of the Th1 pathway in a TNFa depending manner.


Disclosure:

C. I. Daien,
None;

S. Gailhac,
None;

T. Mura,
None;

B. Combe,
None;

M. Hahne,
None;

J. Morel,

Pfizer Inc,

2,

Bristol-Myers Squibb,,

5,

Abbott Laboratories,

5,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5,

Merck Pharmaceuticals,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-levels-of-memory-b-cells-are-associated-with-response-to-a-first-anti-tnf-drug-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology